Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
09:00am, Tuesday, 16'th Sep 2025
CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
Relmada Issues Mid-Year CEO Letter to Shareholders
07:15am, Wednesday, 10'th Sep 2025
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
01:55pm, Friday, 08'th Aug 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Maged S. Shenouda - Chief Financial Officer Raj S.
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
07:00am, Thursday, 31'st Jul 2025
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapi
Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 C
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
08:00am, Wednesday, 09'th Jul 2025
Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative Appointment highlights DIMERx's next phase of growth as it
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
07:00am, Tuesday, 17'th Jun 2025
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., J
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript
10:02pm, Monday, 12'th May 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 12'th May 2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients)
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
07:30am, Thursday, 08'th May 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innov
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
01:38pm, Monday, 28'th Apr 2025
90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
09:00am, Sunday, 27'th Apr 2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
08:00am, Thursday, 24'th Apr 2025
April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES,
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
08:41am, Monday, 14'th Apr 2025
CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presenta
